潜在的可操作的分子变化,特别是与唾液腺癌的不良瘤结果相关的分子变化
Julia Pikul1, Marcin M Machnicki2, Anna Rzepakowska3
1Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Warsaw, Warsaw, Poland.
BMC cancer
|January 8, 2025
概括
唾液腺癌 (SGCs) 呈现出与预后不佳相关的多样化分子特征. 通过下一代测序 (NGS) 识别可操作的突变可以为这些罕见恶性瘤指导个性化治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 唾液腺癌 (SGCs) 是一种异质的罕见恶性瘤群.
- 目前的治疗选择往往不够,突出需要改进预后标志物和向治疗.
研究的目的:
- 为了评估SGC中的分子变化.
- 识别与预后和个性化治疗策略相关的遗传变化.
主要方法:
- 从40个档案SGC组织样本中提取DNA.
- 针对性下一代测序 (NGS) 面板用于突变和拷贝数变异分析.
- 分析的重点是37个瘤,其中有选定的可操作的基因异常.
主要成果:
- NF1 (24%) 和TP53 (22%) 是最常见的基因变异,在不良结果的情况下,变异率更高.
- TP53突变与明显较差的整体存活率相关 (p=0.04).
- 在大多数SGC亚型中确定了可采取行动的变化,在腺状囊性癌 (AdCC) 和腺癌 (AD) 中的百分比很高.
结论:
- SGCs呈现出一个复杂的分子景观,预后不佳,治疗途径有限.
- 下一代测序 (NGS) 分析对于发现可操作的目标至关重要.
- 根据NGS提供的个性化治疗策略,可以改善SGC患者的治疗结果.
更多相关视频
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K


